Biondvax Pharmaceuticals Stock Shares Owned By Insiders
| BVXVDelisted Stock | USD 1.35 0.03 2.17% |
BiondVax Pharmaceuticals fundamentals help investors to digest information that contributes to BiondVax Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of BiondVax Stock. The fundamental analysis module provides a way to measure BiondVax Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BiondVax Pharmaceuticals stock.
BiondVax |
BiondVax Pharmaceuticals Company Shares Owned By Insiders Analysis
BiondVax Pharmaceuticals' Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current BiondVax Pharmaceuticals Shares Owned By Insiders | 20.01 % |
Most of BiondVax Pharmaceuticals' fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BiondVax Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
CompetitionBased on the latest financial disclosure, 20.01% of BiondVax Pharmaceuticals are shares owned by insiders. This is 31.82% higher than that of the Pharmaceuticals sector and 41.11% higher than that of the Health Care industry. The shares owned by insiders for all United States stocks is 98.32% lower than that of the firm.
BiondVax Shares Owned By Insiders Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BiondVax Pharmaceuticals' direct or indirect competition against its Shares Owned By Insiders to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of BiondVax Pharmaceuticals could also be used in its relative valuation, which is a method of valuing BiondVax Pharmaceuticals by comparing valuation metrics of similar companies.BiondVax Pharmaceuticals is currently under evaluation in shares owned by insiders category among its peers.
BiondVax Fundamentals
| Return On Equity | -56.02 | |||
| Return On Asset | -0.31 | |||
| Current Valuation | 21.94 M | |||
| Shares Outstanding | 3.65 M | |||
| Shares Owned By Insiders | 20.01 % | |||
| Shares Owned By Institutions | 10.69 % | |||
| Number Of Shares Shorted | 4.88 K | |||
| Price To Earning | (4.91) X | |||
| Price To Book | 7.48 X | |||
| EBITDA | (10.5 M) | |||
| Net Income | (5.8 M) | |||
| Cash And Equivalents | 14.55 M | |||
| Cash Per Share | 2.23 X | |||
| Total Debt | 21.54 M | |||
| Current Ratio | 1.71 X | |||
| Book Value Per Share | (1.96) X | |||
| Cash Flow From Operations | (7.26 M) | |||
| Short Ratio | 0.32 X | |||
| Earnings Per Share | (2.35) X | |||
| Target Price | 39.0 | |||
| Number Of Employees | 33 | |||
| Beta | 2.37 | |||
| Market Capitalization | 4.97 M | |||
| Total Asset | 27.07 M | |||
| Retained Earnings | (115.83 M) | |||
| Working Capital | 12.03 M | |||
| Current Asset | 36.93 M | |||
| Current Liabilities | 1.7 M | |||
| Z Score | -6.6 | |||
| Net Asset | 27.07 M |
About BiondVax Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BiondVax Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BiondVax Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BiondVax Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Other Consideration for investing in BiondVax Stock
If you are still planning to invest in BiondVax Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the BiondVax Pharmaceuticals' history and understand the potential risks before investing.
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |